03 Nov, 2023 24-Month Results from ILLUMINATE-C Phase 3 Study of OXLUMO® (lumasiran) Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Meeting
New 24-month results from the ILLUMINATE-C Phase 3 study of lumasiran in patients with advanced primary hyperoxaluria type 1 (PH1) were presented at the American Society of Nephrology (ASN) Kidney Week 2023 Meeting. Additional findings from a retrospective study of the natural history of advanced PH1 were also presented.
Lieske, et al. “Lumasiran for Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 24-Month Analysis of the Phase 3 ILLUMINATE-C Trial”
Lieske, et al. “Natural History of Advanced Primary Hyperoxaluria Type 1: A Retrospective Study”